THE WOODLANDS, Texas, June 23, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has commenced enrolling subjects in the 9 mg cohort in the Company’s low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 6 mg dose. No signals of liver toxicity have been detected to date in subjects who were dosed in the 6 mg group.
